Search

These awards recognize scientific excellence in the field of natural products and their applications for health and well-being

We consider these appointments to be key to driving this historic process forward, as it will establish the rules governing European biotechnological innovation over the next two decades and lay the

The incorporation of advanced biotechnological assets—such as proteins, peptides, fermented products, or cell derivatives—adds the challenge of ensuring their robust and reliable manufacture, scaling

Don’t miss the opportunity to secure the best exhibition spaces, explore sponsorship options for maximum visibility, and register to attend one of Europe’s key industry gatherings, offering unique

Marina Salmón, Head of Project Evaluation at the Scientific Foundation of the Spanish Association Against Cancer, a partner of AseBio, analyzes the situation on International Childhood Cancer Day.

The study has been initiated at Hospital La Fe in Valencia and Hospital Clínic Barcelona, two internationally recognized refence centers for acute leukemias and advanced therapies.

Based in New Jersey (USA), to lead ORYZON’s CNS clinical development.

AseBio and the Biotech Platform are launching the fourth edition of “A Day with a Biotech Woman”, enabling young women—the emerging talent of today—to experience and closely follow the work of a

The study, led by Yale University, explore the combination with atezolizumab and radiation therapy.

Two recent reports map Spain’s ecosystem and quantify the economic potential of alternative proteins: up to €10 billion annually and 34,000 jobs in Spain by 2040 under a scenario of moderate support

GENESIS Biomed closes 2025 as its best year ever, with strong growth compared to 2024: 506 projects (+26.5%) and 323 customers (+43.6%).

Dr Ignacio Martín-Loeches joins Viva In Vitro Diagnostics as an advisor to its Medical Advisory Board, further strengthening a committee that already includes Dr Ricard Ferrer Roca (Vall d’Hebron

Despite advances in oncology care, the persistently poor prognosis of pancreatic cancer and rising mortality rates have led to a sustained increase in productivity losses, particularly among the